{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&_properties=answer.isMinisterialCorrection,legislature,houseId,answer.answeringMemberPrinted,tablingMember&hansardHeading=Cannabis:%20Medical%20Treatments", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?_properties=answer.isMinisterialCorrection,legislature,houseId,answer.answeringMemberPrinted,tablingMember&hansardHeading=Cannabis:%20Medical%20Treatments", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&_properties=answer.isMinisterialCorrection,legislature,houseId,answer.answeringMemberPrinted,tablingMember&_metadata=all&hansardHeading=Cannabis:%20Medical%20Treatments", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&_properties=answer.isMinisterialCorrection,legislature,houseId,answer.answeringMemberPrinted,tablingMember&hansardHeading=Cannabis:%20Medical%20Treatments", "isPartOf" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_properties=answer.isMinisterialCorrection,legislature,houseId,answer.answeringMemberPrinted,tablingMember&hansardHeading=Cannabis:%20Medical%20Treatments", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?_properties=answer.isMinisterialCorrection,legislature,houseId,answer.answeringMemberPrinted,tablingMember&hansardHeading=Cannabis:%20Medical%20Treatments", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&_properties=answer.isMinisterialCorrection,legislature,houseId,answer.answeringMemberPrinted,tablingMember&hansardHeading=Cannabis:%20Medical%20Treatments", "type" : "http://purl.org/linked-data/api/vocab#ListEndpoint"}
    , "items" : [{"_about" : "http://data.parliament.uk/resources/1689862", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1689862/answer", "answerText" : {"_value" : "<p>The Department does not hold details relating to the age of people prescribed medicinal cannabis.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
        }
        , "answeringMemberConstituency" : {"_value" : "Pendle"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
        , "dateOfAnswer" : {"_value" : "2024-02-27", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2024-02-27T11:18:22.867Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2024-02-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many people aged under 18 have been prescribed medicinal cannabis as of 19 February 2024.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
      }
      , "tablingMemberConstituency" : {"_value" : "Strangford"}
      , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
      ], "uin" : "14583"}
    , {"_about" : "http://data.parliament.uk/resources/1689392", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1689392/answer", "answerText" : {"_value" : "<p>Licensed cannabis-based medicines are routinely available on the National Health Service. However, clinical guidelines from the National Institute for Health and Care Excellence (NICE) demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.<\/p><p> <\/p><p>The Government continues to call on manufacturers to invest in research and clinical trials to prove if their products are safe and effective and offers scientific and research advice from the Medicines and Healthcare products Regulatory Agency and the NICE.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
        }
        , "answeringMemberConstituency" : {"_value" : "Pendle"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
        , "dateOfAnswer" : {"_value" : "2024-02-21", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2024-02-21T09:43:53.517Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2024-02-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans her Department has to make medicinal cannabis more accessible to those who need it.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4828", "label" : {"_value" : "Biography information for Paula Barker"}
      }
      , "tablingMemberConstituency" : {"_value" : "Liverpool, Wavertree"}
      , "tablingMemberPrinted" : [{"_value" : "Paula Barker"}
      ], "uin" : "14291"}
    , {"_about" : "http://data.parliament.uk/resources/1687065", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1687065/answer", "answerText" : {"_value" : "<p>The Department, via the National Institute for Health and Care Research (NIHR), is developing a programme of two randomised controlled trials to test the safety and efficacy of medicinal cannabis products to treat epilepsy in adults and children. The trials will start as soon as possible, and the results will be published once the trials have completed and the findings peer reviewed.<\/p><p> <\/p><p>Furthermore, the Government continues to encourage manufacturers to invest in research and has highlighted that public funding is available for high quality applications. The Medicines and Healthcare products Regulatory Agency and the NIHR can provide applicants with scientific and research advice.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
        }
        , "answeringMemberConstituency" : {"_value" : "Pendle"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
        , "dateOfAnswer" : {"_value" : "2024-02-09", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2024-02-09T10:47:53.36Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2024-02-02", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what progress she has made with (a) regulatory, (b) research and (c) NHS partners on establishing clinical trials to test the (i) safety and (ii) efficacy of medical cannabis products.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4995", "label" : {"_value" : "Biography information for Sarah Dyke"}
      }
      , "tablingMemberConstituency" : {"_value" : "Somerton and Frome"}
      , "tablingMemberPrinted" : [{"_value" : "Sarah Dyke"}
      ], "uin" : "12872"}
    , {"_about" : "http://data.parliament.uk/resources/1682606", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1682606/answer", "answerText" : {"_value" : "<p>Licensed cannabis-based medicines, that have been proved effective in clinical trials and judged cost-effective by the National Institute of Health and Care Excellence (NICE), are routinely available on the National Health Service, including for people aged over two years old with certain types of epilepsy. However, clinical guidelines from NICE demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.<\/p><p>We continue to call on manufacturers to conduct research to prove if their products are safe and effective and we are working with regulatory, research and NHS partners to establish clinical trials to test the safety and efficacy of these products.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
        }
        , "answeringMemberConstituency" : {"_value" : "Pendle"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
        , "dateOfAnswer" : {"_value" : "2024-01-22", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2024-01-22T14:04:14.56Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2024-01-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the potential merits of allowing children to be issued medical cannabis prescriptions on the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4995", "label" : {"_value" : "Biography information for Sarah Dyke"}
      }
      , "tablingMemberConstituency" : {"_value" : "Somerton and Frome"}
      , "tablingMemberPrinted" : [{"_value" : "Sarah Dyke"}
      ], "uin" : "9974"}
    , {"_about" : "http://data.parliament.uk/resources/1681903", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1681903/answer", "answerText" : {"_value" : "<p>Licensed cannabis-based medicines are available and funded on the National Health Service, where the safety, quality and clinical and cost effectiveness has been assessed and approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence.<\/p><p>The Government continues to encourage manufacturers to develop new treatments and invest in research and clinical trials, and offers scientific and research advice from the MHRA and the National Institute for Health and Care Research.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
        }
        , "answeringMemberConstituency" : {"_value" : "Pendle"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
        , "dateOfAnswer" : {"_value" : "2024-01-17", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2024-01-17T17:12:08.693Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2024-01-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, if she will make an assessment of the effectiveness of medicinal cannabis treatments provided by the NHS; and whether she has plans to increase the number of treatments available.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1447", "label" : {"_value" : "Biography information for Andrew Rosindell"}
      }
      , "tablingMemberConstituency" : {"_value" : "Romford"}
      , "tablingMemberPrinted" : [{"_value" : "Andrew Rosindell"}
      ], "uin" : "9453"}
    , {"_about" : "http://data.parliament.uk/resources/1681904", "AnsweringBody" : [{"_value" : "Department for Business and Trade"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1681904/answer", "answerText" : {"_value" : "<p>The Department for Business and Trade (DBT) actively assists life sciences companies in their endeavours to invest, expand, and export, thereby generating employment and economic growth.<\/p><p>UK-based life sciences businesses receive support from DBT through trade missions to key markets, participation in major trade events, tackling market access barriers, upskilling exporters, and guidance on entering new markets. Although routine assessments of the economic impact of specific life sciences\u2019 subsectors like medicinal cannabis are not conducted, DBT is committed to supporting companies of various sizes throughout their export and inward investment endeavours while adhering to national regulatory guidelines.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4474", "label" : {"_value" : "Biography information for Kevin Hollinrake"}
        }
        , "answeringMemberConstituency" : {"_value" : "Thirsk and Malton"}
        , "answeringMemberPrinted" : {"_value" : "Kevin Hollinrake"}
        , "dateOfAnswer" : {"_value" : "2024-01-23", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2024-01-23T17:59:05.127Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "214"}
      , "answeringDeptShortName" : {"_value" : "Business and Trade"}
      , "answeringDeptSortName" : {"_value" : "Business and Trade"}
      , "date" : {"_value" : "2024-01-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State of Business and Trade, what estimate she has made of the contribution of domestic medicinal cannabis production to the economy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1447", "label" : {"_value" : "Biography information for Andrew Rosindell"}
      }
      , "tablingMemberConstituency" : {"_value" : "Romford"}
      , "tablingMemberPrinted" : [{"_value" : "Andrew Rosindell"}
      ], "uin" : "9454"}
    , {"_about" : "http://data.parliament.uk/resources/1663633", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1663633/answer", "answerText" : {"_value" : "<p>Licensed cannabis-based medicines are routinely available on the National Health Service. However, clinical guidelines from the National Institute for Health and Care Excellence demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.<\/p><p>Funding of unlicensed products is subject to local National Health Service decisions on a case-by-case basis. These decisions follow clearly developed procedures that ensure equitable distribution of funding, prioritising those medicines that have proved their safety, quality, and clinical and cost effectiveness.<\/p><p>We continue to call on manufacturers to conduct research to prove if their products are safe and effective and we are working with regulatory, research and NHS partners to establish clinical trials to test the safety and efficacy of these products.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2023-10-19", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-10-19T14:43:27.227Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-10-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether the Government is taking steps to reduce inequalities in access to medicinal cannabis prescribed under the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4079", "label" : {"_value" : "Biography information for Julian Sturdy"}
      }
      , "tablingMemberConstituency" : {"_value" : "York Outer"}
      , "tablingMemberPrinted" : [{"_value" : "Julian Sturdy"}
      ], "uin" : "201487"}
    , {"_about" : "http://data.parliament.uk/resources/1663778", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1663778/answer", "answerText" : {"_value" : "<p>Licensed cannabis-based medicines are routinely available on the National Health Service. However, clinical guidelines from the National Institute for Health and Care Excellence demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.<\/p><p>Funding of unlicensed products is subject to local NHS decisions on a case-by-case basis. These decisions follow clearly developed procedures that ensure equitable distribution of funding, prioritising those medicines that have proved their safety, quality and clinical and cost effectiveness.<\/p><p>We continue to call on manufacturers to conduct research to prove if their products are safe and effective and we are working with regulatory, research and NHS partners to establish clinical trials to test the safety and efficacy of these products.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2023-10-19", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-10-19T11:14:45.24Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-10-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will take steps to increase access to cannabis-based medicinal products on the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4511", "label" : {"_value" : "Biography information for Dr Rupa Huq"}
      }
      , "tablingMemberConstituency" : {"_value" : "Ealing Central and Acton"}
      , "tablingMemberPrinted" : [{"_value" : "Dr Rupa Huq"}
      ], "uin" : "201631"}
    , {"_about" : "http://data.parliament.uk/resources/1652383", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1652383/answer", "answerText" : {"_value" : "<p>Health Ministers have met with families and patients and have discussed the challenges around the use of unlicensed cannabis-based medicines at great length in Parliament., Ministers are focused on galvanising research to determine if these products are safe and effective and might be funded within the National Health Service.<\/p><p>The National Institute for Health and Care Research and NHS England will be supporting two world-first randomised control trials on cannabinoids in the treatment of epilepsy. When further details on the trials is available, we will ensure the Medcan Family Foundation are informed.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2023-07-17", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-07-17T14:51:28.273Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-07-12", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will meet members of the Medcan Family Foundation to discuss the availability of advanced unlicensed medicinal cannabis for those people who had been diagnosed with childhood epilepsy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/242", "label" : {"_value" : "Biography information for Sir Christopher Chope"}
      }
      , "tablingMemberConstituency" : {"_value" : "Christchurch"}
      , "tablingMemberPrinted" : [{"_value" : "Sir Christopher Chope"}
      ], "uin" : "193547"}
    , {"_about" : "http://data.parliament.uk/resources/1642217", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1642217/answer", "answerText" : {"_value" : "<p>Cannabis based products for medicinal use in humans (CBPMs) is a term that usually designates medicinal products that are not licensed in the United Kingdom. Most CBPMs in use in the UK are unlicensed medicines imported into the Country. Regulation 167 of the Human Medicine Regulations 2012, as amended, allows for medicines without a marketing authorisation, also referred to as a licence, to be supplied under certain circumstances. In the interest of public health, the exemption is narrowly drawn because unlicensed medicines or specials, unlike licensed medicinal products, have not been assessed by the Licensing Authority against the criteria of safety, quality and efficacy.<\/p><p>An unlicensed medicine may be supplied following a bona fide unsolicited order and is formulated in accordance with the specific requirements of the prescriber. This means that the quality, safety and efficacy of unlicensed medicines is the direct responsibility of the prescribers responsible for the care of individual patients as they are the ones that determine if these are fit for purpose.<\/p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) ensures that any importer of an unlicensed medicinal product into the UK must be suitably licensed to import unlicensed medicines and prior to the importation taking place the importer must notify of their intent to import the unlicensed medicine and provide a set of supportive documentation, which the MHRA will assess to ensure the medicine\u2019s quality and safety. This typically includes the requirement that a medicine has been produced in facilities meeting Good Manufacturing Practice or equivalent recognised quality standards for medicines.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2023-06-14", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-06-14T16:50:18.487Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-06-06", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure the (a) quality and (b) safety of imported cannabis-based products for medicinal use; if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1428", "label" : {"_value" : "Biography information for Sir Bill Wiggin"}
      }
      , "tablingMemberConstituency" : {"_value" : "North Herefordshire"}
      , "tablingMemberPrinted" : [{"_value" : "Sir Bill Wiggin"}
      ], "uin" : "187907"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&_properties=answer.isMinisterialCorrection,legislature,houseId,answer.answeringMemberPrinted,tablingMember&hansardHeading=Cannabis:%20Medical%20Treatments", "page" : 0, "startIndex" : 1, "totalResults" : 245, "type" : "http://purl.org/linked-data/api/vocab#Page"}
}